Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the project is to test whether or not the commonly used medication frusemide, given after heart surgery, and aiming to increase urinary output can have an effect on kidney function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

NCT04687800

Cataract

TERMINATED PHASE4

Cataract Surgery on Advanced Age Related Macular Degeneration Patients

NCT04045704

Cataract Macular Degeneration Advanced

WITHDRAWN NA

The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment

NCT00564356

Efficacy Complications

UNKNOWN NA

Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

NCT04752020

Fuchs' Endothelial Dystrophy

COMPLETED EARLY_PHASE1

Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts

NCT02403206

Intumescent Cataract

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients will receive standard supportive care based on current established management practice of cardio-thoracic patients. The only difference in treatment will be the randomisation of patients to receive/not receive protocolised administration of frusemide targeting a urine output.

There will be 2 groups of patients. The control group-which will receive frusemide bolus doses if required as determined by the surgeon/consultant physician. The frusemide infusion group-which will be monitored to achieve a trial specified hourly urine output target range of 1-2mls/kg/hour. In order to achieve this target the patient may need to receive a loading dose of frusemide and may also then require a frusemide infusion. The aim will be to maintain the urine output within the target range for the first 48 hours after cardiac surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Impairment After Cardiac Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Care

Patients will only receive frusemide as per the treating physicians treatment

Group Type OTHER

Frusemide

Intervention Type DRUG

Intervention

Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour

Group Type OTHER

Frusemide

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Frusemide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients admitted for cardiac surgery will be assessed for eligibility. Participants will be approached for inclusion, from the pre-admission clinics and wards of the Cardiothoracic surgery unit. Potential participants will be identified by the daily review of planned cardiothoracic surgery schedule.